Venus Medtech (Hangzhou) Inc.

🌟 Venus Medtech LATAM Heart Valve Intervention Workshop: Innovation Never Stops 🌟 What an incredible Venus Medtech LATAM Heart Valve Intervention Workshop it was! Huge thanks to all our partners who made the Workshop unforgettable. 🫀The 2 pioneering heart valve technologies from the Venus family, Venus-PowerX, the fully-released and retrievable dry-tissue TAVR system, and VenusA-Pro, were on full display throughout the successful workshop and live case transmissions. 👏 Special thanks to Dr. WANG Yan, Dr. WANG Bin, and the entire team from Xiamen Cardiovascular Hospital for generously sharing your invaluable experiences with VenusA-Pro in China. Additionally, we extend our heartfelt appreciation to Dr. Pablo Spaletra from the ICBA institution in Buenos Aires, Argentina, for his insightful contributions on Venus-PowerX, which have greatly enhanced our understanding of the future of TAVR. We also thank the team from the Instituto Nacional del Tórax, to Dr. Dauvergne Christian, Dr. Sandoval Jorge, Dra. Cataldo Pabla, and their team for presenting the remarkable Venus-PowerX case. As we move forward, let's continue to collaborate and innovate, staying committed to excellence in every heartbeat. ❣️ #TAVR# TAVI#dry tissue #retrievable#self-adaptive anti-PVL##Anti-calcification#VenusA-Pro#Venus-PowerX#

✨ Magnify Innovation, Experience Quality at PCR London Valves 2024 ✨

🎖 Big milestone! The first two implantations were completed in Venus-Vitae SMART-ALIGN Pivotal Clinical Study at Prince of Wales Hospital in Hong Kong. Another leap forward for Venus into the frontier of next-generation balloon-expandable dry-tissue valves, representing a significant addition to our innovative transcatheter heart valve solutions. 💜 🧡 Our very special thanks to Dr. Kent Chak Yu So, Dr.Scott Lim, and the great team of Prince of Wales Hospital! 👏 👏 #Venus-Vitae#dry-tissue#TAVR# Balloon-expandable# 

Exciting about the upcoming #SOLACI Buenos Aires Congress, which #VenusMedTech is honored to be part of. We warmly invite you to our exclusive Symposium and Lunch Session where you can experience LIVE demonstrations and gain insights from our experts. VENUSP- VALVE LIVE CASE 🗓️ Date: Wednesday, August 7 📍 Location: Buen Ayre B –Pediatric Room VENUSP- VALVE SYMPOSIUM 🗓️ Date: Thursday, August 8 📍 Location: Buen Ayre B –Pediatric Room VENUSMEDTECH LUNCH SYMPOSIUM 🗓️ Date: Friday, August 9 📍 Location: Main Area–Pacific Room See you in Buenos Aires ! #InnovationNeverStops @SOLACI #TPVR #VenusMedtech #VenusPVALVE #TAVR #Pulmonary

💐 VIVA LA VIDA BUENOS AIRES! 💐 We are delighted to be part of the #SOLACI 2024 Congress! Don't miss the chance to dive into and explore #VenusMedtech LIVE-CASES demonstrations and to hear from the top KOLs at the VenusP-VALVE SYMPOSIUM and VenusMedtech Lunch Session. See you there! #InnovationNeverStops @SOLACI #VenusMedtech #TPVR #TAVR#

👏 The Kick-off Meeting of Venus-Vitae SMART-ALIGN Global Multicenter Pivotal Study was successfully held at Prince of Wales Hospital in Hong Kong! 💐Our very special thanks to Dr.So Chak Yu Kent, Prof. Lee Alex Pui Wai, Dr. Chui Ka Long, and the team at Prince of Wales Hospital. 🧡 As our next-generation balloon-expandable dry-tissue transcatheter heart valve system, Venus-Vitae utilizes the innovative Venus-Endura technology,  features a unique Lockwire Technology, Coronary Alignment technology, as well as self-adaptive anti-PVL technology. Noteworthily, Venus-Vitae was approved in Argentina and Chile in 2022 and 2023 in succession. As we move forward, let's continue to collaborate and innovate, staying committed to excellence in every heartbeat. #TAVR# Balloon-expandable# dry-tissue#Commissures alignment#Adaptive active annular sealing# next-generation valve#Anti-calcification#

💐Exciting news from Venus Medtech! The VenusA-Pro Transcatheter Aortic Valve Replacement (TAVR) System has been approved for marketing in Russia. This represents a significant milestone, accelerating the company's international reach with the VenusA product line. #TAVR#VenusA#VenusA-Pro#SHD#VenusMedtech#heart valve#

❤️ 100 LIVES TRANSFORMED: The VenusP-Valve Reaches a Landmark in the UK!

💜 Eight-year follow-up data of VenusP-Valve impresses at OCC-WCC 2024! 💛 At the 18th Oriental Congress of Cardiology Together with the World Congress of Cardiology (OCC-WCC 2024), Prof. Zhou Daxin from Zhongshan Hospital affiliated to Fudan University, presented the eight-year follow-up data from the China pivotal clinical trial of VenusP-Valve, a transcatheter pulmonic valve replacement (TPVR) system. 🔝 Top Takeaways: Long-term Safety: No increase in cardiac deaths at eight-year compared to one, three, five, and seven years post-procedure; Long-term Efficacy: Good valve function, improved hemodynamics, and sustained patient benefits backed by eight-year post-procedural results; Improved Quality of Life: Six female subjects became mothers during the follow-up period. Following its first clinical implantation in 2013, VenusP-Valve has been applied in clinical practice for 11 years. In June 2024, VenusP-Valve completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine. #TPVR#Pulmonary# Pulmonary regurgitation#CHD#structural heart#VenusP-Valve#OCC#WCC#PROTEUS#IDE#

🎈 Celebrating 15 Years of Success! 🎈  July 3rd marks Venus Medtech's 15th anniversary. We celebrated with pleasure, laughing, and wonderful memories. Here's a look at the great day full of camaraderie and enthusiasm. We couldn't have reached this milestone without YOU - our amazing team, loyal clients, and supportive community. Thank you for being a part of our journey! Look forward to many more prosperous years together. Here's to more growth, innovation, and fun! 🌟🥂  #Venus#Venus Medtech#Anniversary#15th anniversary#TAVR#TTVR#TMVR#TTVR#SHD#Heart Valve#